Abstract
Complete protection against symptomatic malaria and total inhibition of liver- and blood-stage parasites has been observed following the use of a new malaria vaccine in mice [(2001) Proc. Natl. Acad. Sci. U. S. A. 98, 11491–11496]. Nussenzweig and her research team at the New York University School of Medicine applied their new vaccine as a prime-boost strategy. Mice were inoculated with a replication-defective recombinant adenovirus expressing the circumsporozoite protein (CS) of Plasmodium yoelii (AdPyCS) followed by a booster with an attenuated recombinant vaccinia virus also expressing CS (VacPyCS). When the two vaccines were administered separately by eight or more weeks, the researchers noted high levels of activated CS-specific CD8+ and CD4+ T cells, elevated anti-sporozoite antibody titers, and complete and long-lasting protection against disease. This indicates that immunization with AdPyCS generates highly effective memory T and B cells, which can be recalled by boosting with VacPyCS. SHK
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
